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Recent evidence indicates that renin itself might be
profibrotic, independent of angiotensin II; however, the
signaling system by which renin exerts a direct effect is not
known. We tested the hypothesis that renin receptor
activation, in turn, activates the extracellular-signal regulated
kinase 1 and 2 (ERK1/2) of the mitogen-activated protein
kinase system in mesangial cells. Recombinant rat renin
induced a rapid phosphorylation of ERK1/2 and subsequent
cell proliferation in a dose- and time-dependent manner.
ERK1/2 activation by renin addition was not altered by
angiotensin-converting enzyme inhibition or angiotensin
receptor blockade. An ERK kinase inhibitor significantly
reduced the renin-induced ERK1/2 phosphorylation and the
subsequent increase in transforming growth factor-b1
(TGF-b1) and plasminogen activator inhibitor-1 mRNA
expression. A small-inhibiting RNA, siRNA, against the renin
receptor completely blocked ERK1/2 activation by rat renin.
We conclude that renin induces ERK1/2 activation though a
receptor-mediated, angiotensin II-independent mechanism in
mesangial cells. This renin-activated pathway triggers cell
proliferation along with TGF-b1 and plasminogen activator
inhibitor-1 gene expression. This system may play an
important role in the overall profibrotic actions of renin.
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Renin is an aspartic protease known to cleave angiotensino-
gen to generate angiotensin (Ang) I. Ang I is the precursor of
the active end-product of the renin–angiotensin–aldosterone
system (RAAS), Ang II.1 Recent studies suggest that renin, in
addition to its role to convert angiotensinogen to Ang I,
might have direct, receptor-mediated actions.2,3 Renin was
reported to bind to human mesangial cells in culture
inducing hypertrophy and increased plasminogen activator
inhibitor-1 (PAI-1) protein levels. Receptor-bound renin was
neither internalized nor degraded.2 This receptor has been
cloned and is a 350-amino-acid membrane-associated
polypeptide.3 It is also known that renin binding to
mesangial cells in the presence of losartan leads to
intracellular signaling by activating the pathway of the
mitogen-activated protein kinase (MAPK) -1 and -2 (extra-
cellular-signal regulated kinase 1 and 2 (ERK1 and ERK2)).3
We have recently shown that human and rat recombinant
renin, at physiologically relevant concentrations, induces
marked dose- and time-dependent increases in transforming
growth factor-b1 (TGF-b1) in human and rat mesangial cells
that were not altered by addition of losartan or enalapril.4
The actions of rat renin were blocked completely by silencing
the renin receptor with small-inhibiting RNA (siRNA). Taken
together, these studies suggest that renin has novel receptor-
mediated actions, independent of renin’s role in Ang II
generation that could play a role in renal fibrosis. The great
potential clinical relevance of these findings rests in the
possibility that the high plasma and local tissue renin levels
induced by therapeutic Ang II blockade may contribute to
renal fibrosis and thereby limit the effectiveness of this
therapy.
The underlying cellular mechanism for this new renin
action is unclear. It is known that the MAPK signaling
pathways play a pivotal role in induction of cell growth and
differentiation in response to extracellular stimulation.5 The
MAPK signaling pathway is a complex linear kinase cascade
of serine/threonine kinases in which MAPK kinase kinase (or
Raf) phosphorylates and activates MAPK kinase proteins,
which in turn phosphorylate and activate MAPK proteins. At
least seven MAPK kinase homologs and four MAPK families
(ERK1/2, also called as p42/p44 MAPKs, c-Jun NH2 terminal
kinase, P38 and ERK5) have been identified. Among them,
extracellular signal-regulated protein kinase (ERK) is the
most extensively studied. Although its function is typically
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associated with cell proliferative events, it is now clear that
MAPKs function in a more pleiotropic manner to regulate a
variety of cell functions.6 Nguyen et al.3 has shown that
human renin induces activation of ERK1/2 MAPK signaling
independent of Ang II. Here we investigate whether renin
activates this signaling pathway in rat mesangial cells,
whether this activation is receptor mediated, how renin
activation compares with Ang II activation in this system and
whether ERK1/2 MAPK signaling mediates the action of
renin to increase TGF-b and PAI-1, both important
profibrotic molecules.
RESULTS
Renin activates ERK1/2
To investigate involvement of MAPK in renin-mediated TGF-
b1 induction, we first examined the activation kinetics of
ERK1/2 in rat mesangial cells by Western blot analysis using
phospho-specific antibodies. The results, shown in Figure 1,
indicate that addition of 108 M recombinant rat renin
resulted in a rapid and significant activation of ERK1/2.
Phosphorylation of ERK (p-ERK) was significantly increased
at 2.5 min, peaked at 5 min with a 12-fold increase over
control and then remained sixfold elevated until the end of
the 30 min study (Figure 1). The effect of increasing doses of
renin on ERK1/2 phosphorylation at 2.5 min is shown in
Figure 2. ERK1/2 signal was significantly phosphorylated by
renin at concentrations of 1012 M or higher and was greatest
at the highest concentration used (107 M) showing a 4.5-fold
increase over control (Figure 2). Blots for total ERK1/2
signals confirmed that gels were equally loaded. The ratio of
active to total ERK1/2 was determined using the Bio-Rad GS
700 imaging densitometer. These results indicate that renin
activates the ERK pathway in mesangial cells in a time- and
dose-dependent manner.
Renin induces activation of ERK1/2 and subsequent cell
proliferation via the renin receptor, independent of Ang II
Even though reports suggest that mesangial cells have all the
components necessary to synthesize Ang II,7,8 we have
demonstrated previously that the limited amount of
angiotensinogen mRNA present in mesangial cells fails to
produce significant Ang II either in untreated or renin-
treated mesangial cells.4 To further determine renin-induced
ERK1/2 phosphorylation independent of Ang II, cells were
pre-incubated with the angiotensin-converting enzyme
inhibitor enalaprilate (the active form of enalapril) or the
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Figure 1 | Time course of intracellular MAP kinases ERK1/2 phosphorylation in mesangial cells treated with or without renin.
(a) Quiescent rat mesangial cells were incubated in the absence (left blot) or presence of 108 M Renin (right blot) for the indicated times, and
Western blotting was performed. (b) Densitometric analysis of Western blots as shown in (a). The extent of ERK1/2 phosphorylation was
determined by normalizing phospho-ERK1/2 levels to the total ERK1/2. Values are expressed relative to the no-additive, zero-time control,
which was set at unity. *Po0.05 compared to the untreated control.
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Figure 2 | Effect of renin dose on ERK1/2 phosphorylation in
mesangial cells. (a) Quiescent rat mesangial cells were incubated for
2.5 min in the presence of various concentrations of renin, and
Western blotting was performed. (b) Graph shows the relative levels
of intracellular phosphorylated ERK1/2. Values are expressed relative
to the no-additive, control, which was set at unity. *Po0.05
compared to the control.
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angiotensin II type 1 receptor antagonist losartan 30 min at
105 M and then treated with 108 M renin for 15 min. The
results seen in Figure 3a and b revealed that enalaprilate or
losartan treatment had no effect on renin-induced activation
of ERK1/2 signaling.
Since ERK signaling is typically associated with cell
proliferative events, levels of mesangial cell proliferation were
evaluated. During our initial studies, we observed that
primary cultures of mesangial cells in RPMI 1640 with 10%
fetal bovine serum (FBS) grew quickly, reaching B90%
confluence by 24 h. Cell number increased to a greater extent
after 24 h (Figure 4a). Addition of recombinant rat renin in
serum-free RPMI 1640 increased cell proliferation rates in a
dose-dependent manner, compared with cells cultured with-
out renin treatment (Figure 4a). This effect was not altered by
addition of enalaprilate or losartan either, but it was
significantly inhibited by a specific MAPK/ERK kinase inhi-
bitor, 1-,4-diamino-2,3-dicyano-1,4bis[2-aminophenylthio]
butadiene, U0126 (Figure 4b).
As we have previously shown,4 and as shown in Figure 5a
and b, silencing the rat renin receptor by transfecting
mesangial cells for 72 h with 500 pmol StealthTM renin
receptor siRNA effectively reduced the renin receptor to
undetectable levels. This treatment also significantly reduced
renin-induced induction of phospho-ERK1/2 (Figure 5a and
c). Therefore, the mesangial cell renin receptor mediates
renin-induced activation of ERK1/2 signaling and cell
proliferation. Because enalapril and losartan had no effect
on renin-induced induction of phospho-ERK1/2 (Figure 3),
this effect is independent of Ang II generation or action.
The ERK1/2 pathway is involved in the renin-induced
TGF-b1 expression
Since it was previously2,4 shown that renin binding to the
mesangial cell receptor induces PAI-1, TGF-b1, and matrix
proteins fibronectin and collagen I, and we have shown here
that renin-induced phosphorylation of ERK is also receptor-
mediated, we next asked whether activation of the ERK1/2
pathway mediates TGF-b upregulation by renin. To this end,
the specific MAPK/ERK kinase inhibitor U0126 was used.
The efficacy of this inhibitor in our in vitro system is shown
in Figure 6. Addition of 0.1–50 mM U0126 for 10 min
substantially reduced baseline ERK1/2 phosphorylation with-
out renin (Figure 6a). As shown in Figure 6b, the increase in
ERK1/2 phosphorylation seen with renin was decreased
below control values with increasing concentrations of
U0126. In terms of ERK phosphorylation mediating renin-
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Figure 3 | Angiotensin-converting enzyme inhibitor or
angiotensin II type 1 receptor antagonist does not affect
renin-induced ERK1/2 phosphorylation in mesangial cells.
(a) Quiescent mesangial cells were incubated with the
angiotensin-converting enzyme inhibitor enalaprilate (the active form
of enalapril) (Ena) at 105 M, or the angiotensin II type 1 receptor
antagonist losartan (Los) at 105 M or vehicle control for 30 min
before stimulation with 108 M renin for 15 min, and Western
blotting was performed. (b) Graph shows the relative levels of
intracellular phosphorylated ERK1/2. Values are expressed
relative to the no-additive, control (Con), which was set at unity.
*Po0.05 compared to the control.
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Figure 4 | Effect of renin on the proliferation of
mitogen-activated rat mesangial cells. (a) Quiescent rat mesangial
cells were incubated with 10% FBS RPMI 1640 and increasing
concentrations (0–108 M) of renin in serum-free RPMI 1640 for 24 h
(n¼ 8). (b) Quiescent rat mesangial cells were treated with or without
107 M of enalaprilate (Ena), or 107 M of losartant (Los) or 50mM of
U0126, in addition to 109 M of renin for 24 h (n¼ 8). The
administration of 10% FBS was used as the positive control. The
proliferative response was evaluated by MTT assay. Results were
expressed as the mean optical density of MTT absorbance in control
and treated wells. *Po0.05 compared to the untreated control.
#Po0.05 compared to the renin-alone-treated cells.
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induced increases in TGF-b1 mRNA, Northern blotting
revealed that co-incubation of renin with 50 mM U0126 for 2 h
completely prevented the renin-induced increases in TGF-b1
mRNA expression by mesangial cells (Figure 7).
We have previously shown that the renin-induced
increases in mesangial cell PAI-1 originally reported by
Nguyen et al.,2 were in part mediated by renin-induced
increases in TGF-b1 as indicated by the fact that PAI-1
induction by renin was blocked by 68% with excess TGF-b
antibody.4 We now ask whether activation of ERK mediates
renin-induced increases in PAI-1 expression. Mesangial cells
were exposed to 108 M renin and 50 mM U0126 for 2 h. As
shown in Figure 8, the ERK inhibitor U0126 substantially
inhibited both basal and renin-induced increases in PAI-1
mRNA expression. Addition of the TGF-b-neutralizing
antibody, 1D11 (5 mg/ml, R&D Systems Inc., Minneapolis,
MN, USA), and the ERK inhibitor U0126 for 2 h completely
inhibited renin-induced increases in PAI-1 expression
(Figure 9).
DISCUSSION
This study shows that rat renin induces rapid activation of
cellular MAPKs ERK1 and ERK2 in rat mesangial cells,
findings consistent with a previous study using human renin
on human mesangial cells.3 In addition, we show here that
knockdown of the renin receptor with siRNA blocked renin
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Figure 6 | Effect of ERK inhibitor U0126 on cellular baseline or renin-induced cellular ERK1/2 phosphorylation in mesangial cells.
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renin for 10 min, and Western blotting was performed. Graphs show the relative levels of intracellular phosphorylated ERK1/2 (below).
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induction of ERK1/2 phosphorylation indicating that this
effect is renin receptor mediated. Because Ang II blockers
enalapril and losartan had no effect, renin activation of
ERK1/2 is independent of Ang II generation or action. This is
the first direct demonstration that renin triggers intracellular
signaling by binding to renin receptor in addition to its role
in Ang II generation.
It is apparent from previous2,4 and present studies that
renin binds to a cell-member receptor on glomerular
mesangial cells. Through this binding a number of molecules
involved in renal fibrosis are upregulated. This renin receptor
is thought to be a functional renin receptor, different from
the other renin-binding proteins that have been reported.9–11
However, similar functional studies have not been done with
the renin-binding proteins. Further studies are needed to
determine whether there is a cross-talk among these receptors
and binding proteins.
The ability of renin to induce ERK1/2 phosphorylation
raised the question of the subsequent pathophysiological role
of the signaling pathways following activation. ERK1/2 is one
of the cascades of serine/threonine kinases that transduce
signals from the cell surface to the nucleus in response to
growth factors and cellular stress.6,12 ERK pathway activation
is sufficient to drive mitogenesis in many cell types. Recent
data demonstrate that this signaling cascade, traditionally
recognized for its role in growth, also plays a critical role in
other cell functions.6 Renin has been known to induce cell
hypertrophy and proliferation and to upregulate TGF-b1,
PAI-1, and matrix protein production through a receptor-
mediated, Ang II-independent pathway.2,4 The present study
further documented that rat renin promotes mesangial cell
proliferation. The renin-induced hyperproliferative pheno-
type in rat mesangial cells was mediated by ERK activation
through Ang II-independent pathway since the increased
mitotic activity was reversed by the ERK1/2 kinase inhibitor,
U0126, and not by Ang II blockade, enalaprilate, or losartan.
The present study also adds data indicating that renin
induction of TGF-b1 production in rat mesangial cells is
dependent on signaling through ERK1/2, providing an
important link between renin and its potentially important
profibrotic, angiotensin II-independent action. Renin binds
to its receptor to activate the ERK MAPK and subsequent
signaling that leads to cell proliferation and TGF-b induction.
Further studies are required to determine whether renin
activates other members of the MAPK family such as p38
MAPK and c-Jun NH2 terminal kinase.
Very recently, it was first observed by Saris et al. that
human prorenin concentration-dependently activated p38
MAPK and simultaneously phosphorylated Hsp-27 in
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neonatal rat cardiomyocytes, independent of Ang II genera-
tion and M6P receptor.13 Through its regulation of actin
filament dynamics, Hsp-27 is believed to be involved in
maintaining the integrity of cell architecture, growth,
motility, survival, and death.14 Protesome differential display
experiments supported the downstream effects of Hsp-27 on
actin cytoskeleton, suggesting the potential role of prorenin-
induced signaling in the severe cardiac hypertrophy. This
action of prorenin may be consistent with the previous report
in rats with hepatic prorenin overexpression.15 In contrast,
human prorenin application to cardiomyocytes did not result
in detectable ERK1/2 MAPK activation or PAI-1 release as
renin did in mesangial cells. Increased PAI-1 only occurred
when both human angiotensinogen and prorenin were
added. Eprosartan, but not PD123319 (antagonist of AT2-
subtype receptor) or mannose 6-phosphate (M6P), blocked
this effect.13 It has been shown that the specific renin receptor
binds prorenin as effectively as it binds renin. Prorenin
bound to this receptor cleaves angiotensinogen with kinetics
similar to that of fully active renin in solution.16 Therefore,
these data from Saris et al. indicate that increased PAI-1
secretion in neonatant rat cardiomyocytes stimulated by
human prorenin is entirely dependent on Ang II generation
and subsequent AT1 receptor activation. Although it is not
known whether there is the species specificity of the receptor-
prorenin binding, renin and prorenin seem to trigger
different cellular signaling. The clarified receptor-mediated
action of prorenin and its cellular action remain to be further
determined.
TGF-b and PAI-1 are both key mediators of tissue
fibrosis.17 TGF-b1 enhances both extracellular matrix synthe-
sis and extracellular matrix deposition.18,19 TGF-b1 also
increases PAI-1 production whereby plasmin generation is
decreased, protease-dependent fibrinolytic activity is de-
creased and matrix turnover is decreased.20,21 Renin treat-
ment increases both TGF-b1 and PAI-1 production2,4 and we
have previously shown that renin increases PAI-1 through
both TGF-b1-dependent and -independent pathways because
addition of the TGF-b neutralizing antibody, 1D11,4 only
partially blocks the renin-induced increase in PAI-1. In the
present study, the renin-induced increase in PAI-1 expression
is completely inhibited by treatment with the ERK inhibitor,
U0126. This suggests that both the TGF-b-dependent and
TGF-b1-independent pathways by which renin increases PAI-1
are mediated by ERK phosphorylation. Also suggesting that
TGF-b1 induces PAI-1 expression through the ERK-MAPK
pathway are data showing that TGF-b stimulation of rat
mesangial cell PAI-1 mRNA is significantly inhibited by the
specific MAPK kinase inhibitor, PD98059 or U0126.22,23
Therefore, both renin and TGF-b1 appear to share common
elements in the downstream signaling cascades involved in
PAI-1 upregulation. Taken together, our findings suggest that
the receptor-mediated activation of the ERK1/2 signaling
pathway is an important molecular mechanism by which
renin can increase expression of molecules implicated in
renal fibrosis.
Of interest is work where a human renin receptor
transgenic rat was developed to study the mechanisms
underlying the pathogenic effects of (pro)renin receptor
activation in diabetic nephropathy.24 Because cell culture data
showed increased binding of renin and prorenin at the cell
surface after transfection of human or rat renin receptor
cDNA,3,25 the human receptor transgenic animals would be
expected to bind rat prorenin/renin in vivo and activate the
human receptor. These animals were found to have higher
levels of cyclooxygenase 2 and increased ERK1/2 activation in
renal cortex.24 Although receptor activation was not proven
directly, and renin and prorenin effects were not distin-
guished, the data indicate that human (pro)renin
receptor directly or indirectly contributes to cellular ERK
signaling in vivo, as it does in vitro in the present study, and
this signaling may have profibrotic consequences in kidney
disease.
Many molecules activate the MAPK pathway, particularly
in the RAAS. Ang II, as a critical effecter of the RAAS,
stimulates the activation of ERK in cultured mesangial cells.26
Ang II-induced increases in protein synthesis and hyper-
trophy in mesangial cells have been shown to involve
ERK activation.26 Furthermore, Ang II-mediated increases
in TGF-b1 and PAI-1 mRNAs were inhibited by U0126 or
PD98059, which selectively blocks the activity of ERK
pathway at the level of MAPK kinase (MEK).27,28 These data
indicate that activation of MAPK pathway is one of impor-
tant events involved in a variety of responses induced by Ang II
to stimulate extracellular matrix accumulation in mesangial
cells. Similarly, aldosterone, a potent effector molecule in the
RAAS, was also demonstrated recently to stimulate prolifera-
tion of mesangial cells by activating ERK1/2.29,30 Although
there are no data available linking aldosterone-induced
MAPK1/2 signaling to matrix protein expression by mesan-
gial cells, it has been shown that aldosterone stimulates
collagen gene expression and synthesis via activation of
ERK1/2 in rat renal fibroblasts.31 Also, chronic aldosterone/
salt treatment of non-nephrectomized rats induces severe
glomerular mesangial injury and tubulointerstitial fibrosis
beyond aldosterone effects on blood pressure and hemo-
dynamic changes. This damage is associated with the activation
of MAPKs including ERK1/2.32 These data indicate that
MAPKs are important signaling molecules mediating aldos-
terone-induced renal injury and possibly renal fibrosis. The
results of the present study, as well as previously published
data, suggest that the three primary effector molecules of the
RAAS may promote growth and renal damage through a
common pathway involving ERK stimulation that is
independent of the effects of Ang II as a vasoconstrictor,
independent of renin’s role as an aspartyl protease, and
independent of the effects of aldosterone as a regulator of
sodium and volume. In addition, there is some evidence that
RAAS components act synergistically. Min et al.33 reported
that Ang II and aldosterone synergistically activate ERK
signaling and thereby synergistically induce cellular mito-
genic responses. It will be of interest to determine whether
50 Kidney International (2007) 72, 45–52
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renin and Ang II or renin and aldosterone have synergistic
effects on ERK signaling and induction of profibrotic
proteins or whether they simply back up one another in
the fibrotic milieu. Such studies will expand our under-
standing of the roles of all RAAS components in tissue
fibrosis.
In conclusion, this study demonstrates that rat renin
rapidly and dramatically activates intracellular ERK MAPK
signaling by mesangial cells through a receptor-mediated
mechanism, independent of Ang II generation or action.
Renin-induced phosphorylation of ERK1/2 in turn triggers
cell proliferation and cellular TGF-b1 and PAI-1 gene
overexpression. The data presented indicate that the renin-
induced ERK pathway could play a role in renal fibrosis.
Considering that both Ang II and aldosterone, the two other
major components of RAAS, also exert their profibrotic
effects via the MAPK pathway, and considering that Ang II
and aldosterone synergistically induce hypertrophy through
activated ERK signaling, the demonstration here that MAPK
signaling mediates renin’s profibrotic actions raises the
intriguing possibility that blockade of this common signaling
pathway may result in more effective therapy.
MATERIALS AND METHODS
Reagents
Rat recombinant renin was made as described previously.4 A specific
MAPK/ERK kinase inhibitor, U0126 was purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA). Unless otherwise
indicated, other reagents were purchased from Sigma (St Louis, MO,
USA).
Rat mesangial cell culture
Rat mesangial cells were derived from intact glomeruli of four- to
six-week-old Wistar rats and characterized according to published
methods.34,35 Cells were used between passages 4 and 7 and were
maintained in RPMI 1640 medium supplemented with 20% FBS
(Hyclone Laboratory, Logan, UT), 100 U/ml penicillin, 100mg/ml
streptomycin, 0.66 U/ml insulin, 25 mmol N-2-hydroxyethylppiper-
azine-N0-2-ethanesulfonic acid (HEPES) buffer at 371C in a 5% CO2
incubator. Subconfluent mesangial cells seeded on six-well plates
were made quiescent by serum-free medium for 48 h before
experimental studies.
Cellular proliferation and ERK activation
Mesangial cell mitotic activity was evaluated using an MTT (3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) cell pro-
liferation assay according to the manufacturer’s instruction. The
MTT assay is colorimetric method for determining the total number
of viable cells. The yellow tetrazolium MTT is reduced by
dehydrogenase in mitochondria of live cells and lead to the resulting
intracellular purple formazan, which can be solubilized and
quantified by an enzyme-linked immunosorbent assay plate reader.
The proliferative viability of cells corresponds to the amount of
MTT reduced. Our preliminary study confirmed a significant
correlation between counted cell numbers and optical density
values at 520 nm. Each experiment was typically performed with
n¼ 8 separate wells of mesangial cells in 96-well plates under
identical conditions. The administration of 10% FBS was used as the
positive control.
Cellular ERK activation was measured by Western blotting as
levels of phosphorylation of ERK using mouse monoclonal anti-
phospho-pERK1/2 MAPK(Tyr204) E4 monoclonal antibody and
rabbit anti-total ERK1/2 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA). The immunostaining was visualized by enhanced
chemiluminescense (ECL)TM Western blotting detection reagents
(Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire,
UK). Quantitation of the bands on autoradiograms was performed
using a Bio-Rad GS 700 imaging densitometer. Changes in
phosphate ERK1/2 were determined by correcting the densitometric
intensity of its total EKR1/2 for each sample. For comparison, this
ratio was set at unity for normal control samples and other lanes on
the same gel were expressed as fold-increase over this value.
StealthTM RNA interference
Before transfection, rat mesangial cells of 50% confluence were
maintained in 2.5% fetal calf serum medium and then transfected
with lipofectamineTM 2000 (Invitrogen Life Technologies Inc.,
Gaithersburg, MD, USA) and rat renin receptor StealthTM siRNA
as described previously.4 Briefly, cells were transfected with 500 pmol
StealthTM siRNA complexed with lipofectamineTM 2000 (This
condition was determined previously to induce a 75% reduction
in receptor mRNA expression at 72 h incubation4) in 500 ml Opti-
minimum essential medium (MEM) (Invitrogen Life Technologies
Inc.) at 371C in a CO2 incubator, following the siRNA transfection
protocols provided by Invitrogen Life Technologies Inc. Opti-MEM
medium with and without lipofectamineTM 2000 were added to cells
as controls. After a 48 h transfection, medium was replaced with
serum-free and antibiotic-free RPMI 1640. Cells were then made
quiescent for 24 h. After a total transfection of 72 h, cells were
treated with 108 M renin for 10 min for analysis of ERK1/2 signaling
after renin receptor depletion. Rat renin receptor mRNA levels were
determined using Northern blot assay.
Cellular RNA isolation and Northern blot analysis
Total RNA was isolated from rat mesangial cells using TrizolTM
reagent (Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s instructions. Northern blotting was performed using
Ambion’s NorthernMax Gly System (Austin, TX, USA) as described
previously. Probes were labeled with 32P using the Strip-EZ labeling
kit (Ambion) and hybridized overnight in Ultrahyb hybridization
buffer (Ambion). After washing, blots were exposed to films that
were scanned and analyzed by densitometry. Changes in mRNA
levels were determined by correcting the densitometric intensity of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for each
sample to correct for loading variations. For comparison, this ratio
was set at unity for normal control samples, and other lanes on the
same gel were expressed as fold-increase over this value. Probes used
included cDNAs for TGF-b1, PAI-1, rat renin receptor cDNA, and
GAPDH and were used as previously described.36
Statistical analysis
Results are presented as mean7s.d. A value of Po0.05 was
considered statistically significant (Student’s t-test). Duplicate wells
were analyzed for each experiment, and each experiment was
performed independently at least three times.
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